Press release·08/07/2026 00:24:20

Overview of Nutex Health’s Financial Performance

Nutex Health, a leading healthcare provider, has reported its financial results for the three and six months ended June 30, 2026. The company operates three main business segments: the hospital division, the population health management division, and the real estate division.

For the three months ended June 30, 2026, Nutex Health reported net income attributable to the company of $65.8 million, or $9.38 per diluted share, compared to a net loss of $17.7 million, or $2.95 per share, for the same period in 2025. This significant improvement was driven by several key factors:

• Higher patient visits, which increased by 9.6% during the quarter compared to the prior year period.
• Lower hospital division revenue of $201.9 million, a decrease of $34.5 million compared to the same quarter in 2025, primarily due to positive adjustments to variable consideration realized in 2025.
• Significantly lower stock-based compensation expenses related to under construction and ramping hospitals, down $75.9 million compared to the prior year quarter.
• Higher income tax expense of $20.8 million, up $13.2 million from the same quarter in 2025.

For the six months ended June 30, 2026, Nutex Health reported net income attributable to the company of $112.6 million, or $15.87 per diluted share, compared to net income of $3.5 million, or $0.55 per share, for the same period in 2025. The key drivers were similar to the quarterly results, including higher patient visits, lower hospital division revenue, and significantly lower stock-based compensation expenses.

Revenue and Profit Trends

Nutex Health’s hospital division, which accounts for the majority of the company’s revenue, saw a 14.6% decrease in revenue to $201.9 million for the three months ended June 30, 2026, compared to $236.3 million in the prior year period. This decrease was primarily attributed to positive adjustments to variable consideration realized in 2025 as the company experienced early success with the independent dispute resolution (IDR) process. Revenue related to same hospitals decreased by 12.1%.

Despite the lower revenue, the hospital division’s gross profit increased by 13.0% to $141.8 million during the three months ended June 30, 2026, compared to $125.6 million in the same period in 2025. This improvement was primarily driven by a significant decrease in the total cost of arbitration, which was $(12.5) million in the 2026 quarter compared to $48.0 million in the 2025 quarter.

The decrease in arbitration costs was due to two key factors:

1. An amendment to Nutex’s agreement with its third-party arbitration services provider, HaloMD, which transitioned the fee payment structure to a pay-on-collected basis rather than payment due upon award determination. This change contributed $38.4 million to the reduction in contract services expense.

2. A reduction by the Centers for Medicare & Medicaid Services (CMS) and other federal agencies of the administrative fee for the federal IDR process from $115 to $15 per party per dispute, effective June 11, 2026. This fee reduction contributed $4.3 million to the decrease in contract services expense.

Based on current expectations, Nutex anticipates these favorable changes will lead to an approximately 25-30% reduction in its normalized historical contract services expenses going forward.

The population health management division saw revenue increase to $8.9 million for the three months ended June 30, 2026, up from $7.7 million in the prior year period, primarily due to increased membership. This division had a loss before income taxes of $0.5 million in both the 2026 and 2025 quarters, as the company continues to focus on growing this business through the addition of new independent physician associations.

Strengths and Weaknesses

One of Nutex Health’s key strengths is its ability to navigate the complex federal arbitration process for out-of-network claims under the No Surprises Act (NSA). The company’s partnership with HaloMD, a third-party expert in independent dispute resolution, has been crucial in determining which claims to submit for arbitration and managing the submission process. This has allowed Nutex to achieve favorable outcomes, with providers prevailing in approximately 88% of payment determinations during the first half of 2025.

Additionally, the company has benefited from regulatory changes that have reduced the administrative costs associated with the arbitration process, such as the CMS fee reduction. These cost savings have flowed directly to Nutex’s bottom line, contributing to the significant improvement in profitability.

However, the company’s reliance on the IDR process also represents a potential weakness. The federal IDR framework has experienced significant operational challenges, including severe processing backlogs and prolonged determination timelines. While regulatory updates are intended to improve the system’s efficiency over time, the immediate implementation of these changes has introduced further volatility and complexity.

Consequently, Nutex must continually re-evaluate the expected transaction prices for its out-of-network services, which can result in significant fluctuations in recognized revenue from period to period. This uncertainty around the timing and impact of IDR updates poses a risk to the company’s financial performance.

Another potential weakness is the company’s exposure to regulatory changes in the healthcare industry, such as the implementation of value-based reimbursement models and evolving data privacy and security requirements. These changes could impact Nutex’s operations and financial results, and the company must remain vigilant in ensuring compliance with all applicable laws and regulations.

Outlook for the Future

The healthcare industry, particularly emergency care hospitals, continues to face ongoing regulatory uncertainty. Changes in federal or state healthcare laws, regulations, funding policies, or reimbursement practices could significantly impact Nutex’s future revenue and operations.

For example, the No Surprises Act, which prohibits providers from charging patients an amount beyond the in-network cost-sharing amount for certain out-of-network services, may limit the amounts Nutex can receive for its services. Any reduction in the rates the company can charge or the amounts it can receive will reduce its total revenue and operating margins.

Additionally, the federal IDR process is expected to continue evolving. While the recent regulatory changes and the company’s partnership with HaloMD have helped mitigate the impact of the IDR framework’s challenges, future federal court decisions and regulatory modifications may adversely affect Nutex’s ability to collect the revenue it believes is fair and reasonable for its services.

The company is also subject to various state laws and regulations, including those related to the corporate practice of medicine and fee-splitting, which could lead to adverse judicial or administrative action, civil or criminal penalties, or the need to restructure the company’s arrangements with affiliated professional entities and physician partners.

Despite these regulatory uncertainties, Nutex remains focused on growing its business and improving its financial performance. The company’s strategic priorities include continued expansion of its hospital and population health management divisions, as well as exploring opportunities to leverage its real estate assets.

To support these growth initiatives, Nutex has implemented a $25 million stock repurchase program, which it believes will increase shareholder value and offset dilution from the issuance of additional shares. The company has also entered into settlement agreements with certain former doctor owners of under-construction hospitals, retiring a portion of the shares issuable to satisfy those obligations.

Overall, Nutex Health’s financial performance has shown significant improvement, driven by its success in navigating the complex IDR process and the favorable regulatory changes that have reduced its arbitration-related costs. However, the company continues to face challenges from the evolving healthcare landscape and must remain vigilant in managing its regulatory compliance and operational risks. Investors should closely monitor Nutex’s ability to adapt to these changes and maintain its competitive position in the market.